Details for: SLC16A12 AS1

Gene ID: 101926906

Gene Type:  ncRNA (Non-coding RNA)  - A functional RNA molecule that is transcribed from DNA but not translated into a protein. Includes classes like miRNA and lncRNA.

Symbol: SLC16A12 AS1

Ensembl ID: ENSG00000234452

Description: SLC16A12 antisense RNA 1

Selected Context(s):  Overall

Cell Significance Landscape

Contexts:

Significant Cells

Cell Significance Index (CSI) scores for the chosen context(s)

  • mural cell CL0008034
    CSI 14.78
    rCSI 50.08%
    PRS 96.24
  • pericyte CL0000669
    CSI 10.57
    rCSI 28.14%
    PRS 83.06
  • conventional dendritic cell CL0000990
    CSI 6.25
    rCSI 5.22%
    PRS 92.53
  • CD8-positive, alpha-beta memory T cell, CD45RO-positive CL0001203
    CSI 1.13
    rCSI 1.37%
    PRS 85.44

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this specific cell.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.

Cell ID: Standard Cell Ontology term used for mapping and comparing cells across experiments. Ensures consistency in analyzing cellular functions across tissues.
Fold Change: Represents the ratio of the current Cell Significance Index to the Cell Significance Index Threshold, indicating how much the gene expression has changed compared to a baseline.
Cell Significance Index: Reflects how strongly a gene is expressed in this cell type. Calculated using techniques like effect size estimation and bootstrapping for reliability.
Network Configuration

Explore relationships of the current gene. Select an Interaction Source: 'ONTOLOGY' for shared pathways (GO/Reactome) or 'STRING' for protein-protein interactions. Further refine by selecting context genes and comparing Cell Significance Index (CSI) scores between baseline and target cell types and their specific contexts.

Comma-separated if multiple.
Comma-separated if multiple.
Legend:
  • Query Gene
  • Node Color (Target Cell CSI, relative to current network):
    • Very High
    • High
    • Medium
    • Low
    • Very Low
    • CSI N/A
  • Node Size: Proportional to Target Cell CSI magnitude
  • STRING PPI Edge
  • Shared Pathway Edge (ONTOLOGY)

Loading network (please wait)...

Other Information

This section provides additional information about the gene, including a description generated by an AI language model and details about associated proteins.

## Summary [SLC16A12 AS1](/details-gene/101926906) is a non-coding antisense RNA located on chromosome 10q23.31. As an antisense transcript to the solute carrier gene *SLC16A12*, its primary function is likely related to the post-transcriptional regulation of its sense counterpart. **Overall** expression analysis indicates that [SLC16A12 AS1](/details-gene/101926906) is a highly significant marker for cells associated with the microvasculature, particularly [mural cells](/details-cell/CL0008034) and [pericytes](/details-cell/CL0000669). Its expression is also noted, albeit at lower significance, in specific immune cell subsets such as [conventional dendritic cells](/details-cell/CL0000990), suggesting a potential role in modulating both vascular and immune functions. ## Cellular Roles and Expression Landscape The expression profile of [SLC16A12 AS1](/details-gene/101926906) strongly points to a specialized role in the structural components of blood vessels. It shows the highest significance in [mural cells](/details-cell/CL0008034) (CSI: 14.78) and [pericytes](/details-cell/CL0000669) (CSI: 10.57), which are critical for the development, stability, and function of the microvasculature. This specific expression pattern suggests that [SLC16A12 AS1](/details-gene/101926906) may be involved in regulating processes fundamental to the identity and maintenance of these perivascular cell types. Beyond its primary vascular context, [SLC16A12 AS1](/details-gene/101926906) is also significantly expressed in [conventional dendritic cells](/details-cell/CL0000990) (CSI: 6.25) and, to a lesser extent, [CD8-positive, alpha-beta memory T cells, CD45RO-positive](/details-cell/CL0001203) (CSI: 1.13). This dual expression landscape in both vascular and immune cells may indicate a role in coordinating vascular-immune interactions, potentially influencing immune cell trafficking or the metabolic state of antigen-presenting cells within tissues. ## Pathways and Molecular Function Detailed functional annotations for [SLC16A12 AS1](/details-gene/101926906) are not available. However, based on its classification as an antisense RNA, its primary molecular function is predicted to be the regulation of the *SLC16A12* gene. *SLC16A12* encodes a monocarboxylate transporter (MCT12) involved in the transport of creatine and other solutes. Therefore, it is plausible that [SLC16A12 AS1](/details-gene/101926906) modulates cellular metabolism and solute balance in [pericytes](/details-cell/CL0000669) and [dendritic cells](/details-cell/CL0000990) by controlling the local expression of its sense target, *SLC16A12*. This regulatory action could be crucial for maintaining vascular integrity or shaping immune responses. ## Research Directions The specific expression of [SLC16A12 AS1](/details-gene/101926906) in vascular and immune cells, coupled with its presumed regulatory function, opens several avenues for investigation. **Proposed Hypotheses:** 1. **Vascular Stability:** [SLC16A12 AS1](/details-gene/101926906) acts as a negative regulator of *SLC16A12* expression in [pericytes](/details-cell/CL0000669), thereby controlling pericyte contractility and microvascular stability. Dysregulation of this antisense transcript could contribute to pathologies characterized by vascular leakage or abnormal angiogenesis, such as diabetic retinopathy or tumor development. 2. **Immune Metabolism:** In [conventional dendritic cells](/details-cell/CL0000990), [SLC16A12 AS1](/details-gene/101926906) fine-tunes the expression of *SLC16A12* to modulate the metabolic state required for antigen presentation and T-cell activation. Its expression may change dynamically upon dendritic cell maturation or exposure to inflammatory stimuli. **Experimental Approach:** To test the primary hypothesis regarding its regulatory role in [pericytes](/details-cell/CL0000669), a loss-of-function study could be performed. Human primary [pericytes](/details-cell/CL0000669) could be transfected with antisense oligonucleotides (ASOs) or siRNAs designed to specifically degrade [SLC16A12 AS1](/details-gene/101926906) transcripts. The effect of the knockdown on the mRNA and protein levels of the sense gene, *SLC16A12*, would be quantified by qRT-PCR and Western blot, respectively. A significant increase in *SLC16A12* expression following [SLC16A12 AS1](/details-gene/101926906) knockdown would validate its role as a negative regulator. **Therapeutic Potential:** As a non-coding RNA with a highly specific expression pattern, [SLC16A12 AS1](/details-gene/101926906) represents an attractive therapeutic target. Given its localization to perivascular cells, it could be implicated in diseases involving microvascular dysfunction. If its overexpression contributes to pathology (e.g., by suppressing a protective function of *SLC16A12*), targeted **inhibition** using RNA-based therapeutics like ASOs could be a viable strategy. The specificity for [pericytes](/details-cell/CL0000669) might allow for localized treatment of diseases like cancer or ischemic retinopathies while minimizing systemic side effects.